Prostate cancer most often develops from prostatic intraepithelial neoplasia (PIN) in the prostate gland and can be described as localised, locally advanced or advanced (metastatic). Symptoms may include genito-urinary symptoms such as poor urinary stream and erectile dysfunction, or bone pain in cases where the disease has spread to the bones.
Prostate cancer is considered a slow growing cancer and is driven by the androgen axis. Subsequently, treatment for hormone sensitive prostate cancer (HSPC) revolves around androgen deprivation therapy (ADT) alongside radiation therapy and chemotherapy.
Related news and insights
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Lynparza
Pfizer announced positive topline results from the Phase III TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide) compared to placebo plus Xtandi in men with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations.
Clovis Oncology announced positive top-line data from the Phase III, open-label, multicenter, randomized TRITON3 trial demonstrating that Rubraca (rucaparib) monotherapy treatment achieved the primary endpoint of significantly improved radiographic progression-free survival (rPFS) by independent radiology review (IRR) compared with the control group, which consisted of physician’s choice of docetaxel, abiraterone acetate, or enzalutamide